Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-223575 in Dry Eye Disease
NCT02435914Phase 2Completed
- Sponsor
- Allergan
- Start
- Jun 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in dry eye disease (DED), sponsored by Allergan. Started Jun 2015; status: completed.
02
Drugs
regorafenib
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT02435914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02435914.